Dual immunomodulatory and antileishmanial potential of TLR7/8 agonists against Leishmania donovani
Infection and Immunity · 2025
DOI: 10.1128/iai.00323-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infection and Immunity, 2025. Verfasst von Shivani Thakur und 6 weiteren Autor:innen. Beteiligte Einrichtung: Parasitology Laboratory, Department of Zoology, Panjab University, Chandigarh, India. Hauptthemen laut MEDLINE: Leishmania donovani, Toll-Like Receptor 7, Toll-Like Receptor 8, Antiprotozoal Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Council of Scientific & Industrial Research.
Abstract (Originalsprache)
Visceral leishmaniasis (VL), caused by Leishmania donovani , is a neglected tropical disease with limited therapeutic options and increasing drug resistance. This study investigates the immunological mechanisms and antiparasitic efficacy of imidazoquinoline-based Toll-like receptor 7/8 (TLR7/8) agonists as host-directed agents in an in vitro VL model. Using RAW 264.7 macrophages and L. donovani promastigotes and amastigotes, we examined macrophage activation, nitric oxide (NO) induction, and cell cycle disruption in parasites. The lead compounds (5 and 10) significantly enhanced NO production in macrophages, both in unstimulated and LPS-stimulated conditions, indicating robust innate immune activation. Additionally, parasite-derived reactive oxygen species (ROS) levels were markedly elevated, suggesting oxidative stress as a mechanism of direct leishmanicidal action. Flow cytometric analysis revealed G 0 /G 1 arrest in treated promastigotes, further supporting interference with parasite proliferation. Importantly, these compounds exhibited low cytotoxicity toward host cells and favorable selectivity indices. Notably, this is the first in vitro study to comprehensively demonstrate the ability of TLR7/8 agonists to exert direct parasiticidal effects along with immune modulation in the context of VL. The results underscore the potential of TLR-targeted immunomodulation to enhance host defense mechanisms against intracellular protozoan infections and contribute to the development of novel immunopharmacological interventions for VL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Parasitology Laboratory, Department of Zoology, Panjab University, Chandigarh, India.
- Department of Chemistry and Centre of Advanced Studies in Chemistry, Panjab University, Chandigarh, India.
- National Interdisciplinary Centre of Vaccine, Immunotherapeutics and Antimicrobials (NICOVIA), Panjab University, Chandigarh, India.
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, Mohali, Punjab, India.
ORCID-Profile: Shivani Thakur, Kushvinder Kumar, Deepak B Salunke, Sukhbir Kaur
Förderung
- Council of Scientific & Industrial Research
Zitieren
APA
Thakur, S., Kaushik, D., Kumar, K., Kaur, S., Kumar, R., Salunke, D. B., & Kaur, S. (2025). Dual immunomodulatory and antileishmanial potential of TLR7/8 agonists against Leishmania donovani. Infection and Immunity. https://doi.org/10.1128/iai.00323-25
Vancouver
Thakur S, Kaushik D, Kumar K, Kaur S, Kumar R, Salunke DB, et al. Dual immunomodulatory and antileishmanial potential of TLR7/8 agonists against Leishmania donovani. Infection and Immunity. 2025. doi:10.1128/iai.00323-25
BibTeX
@article{Thakur2025,
author = {Thakur, Shivani and Kaushik, Deepender and Kumar, Kushvinder and Kaur, Sandeep and Kumar, Ravinder and Salunke, Deepak B and Kaur, Sukhbir},
title = {Dual immunomodulatory and antileishmanial potential of TLR7/8 agonists against Leishmania donovani},
journal = {Infection and Immunity},
year = {2025},
doi = {10.1128/iai.00323-25}
}
EUVIMED